Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus" proprietary protein crystallization technology. ALTU-238 is a ready-to-use liquid suspension of crystallized rhGH that preserves the structure of the rhGH molecule without the need for pegylation, polymerization, or encapsulation and enables administration through a fine gauge needle. The Phase 2 ALTU-238 pediatric trial is being conducted in approximately 18 clinical sites in the U.S. and targets enrolling 36 growth hormone deficient pediatric patients. ALTU-238 has been studied in a series of Phase 1 and Phase 2 studies in healthy and GH deficiency adults.

Teens Sensitive To Others' Perceptions Of Them
Young adolescents care a lot about what others think about them. A new study confirms this using brain-mapping techniques that shed new light on this complex period of social development.
News of the day
Even Healthy Lungs Labor At Acceptable Ozone Levels
Ozone exposure, even at levels deemed safe by current clean air standards, can have a significant and negative effect on lung function, according to researchers at the University of California Davis.
Medical Devices

Exercise Helps Patients With Non-Alcoholic Fatty Liver Disease

Counseling patients with non-alcoholic fatty liver disease (NAFLD) on how to increase physical activity leads to health benefits that are independent of changes in weight. These findings are in a new study in the July issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience. NAFLD is the most common form of chronic liver disease in developed countries. It is associated with the metabolic syndrome, which also includes obesity, insulin resistance and type 2 diabetes, and is characterized by elevated liver enzymes. Currently, patients with NAFLD are encouraged to alter their lifestyles, however the focus has been on weight loss through dietary changes. The effects of increasing physical activity alone have not been thoroughly investigated. Researchers led by Jacob George of Sydney West Area Health Service in Australia, examined the health outcomes of patients who were counseled on how to increase physical activity. They prospectively enrolled 141 patients with NAFLD from the Sydney West Area Health Service. The participants were divided into a control group, a low-intensity lifestyle intervention group, and a moderate-intensity lifestyle intervention group. The patients in the intervention arms worked with exercise scientists who provided individually tailored counseling on how to increase both planned and incidental physical activity. Walking was the main type of exercise discussed and patients were encouraged to be active for at least 150 minutes per week. After three months, participants in the intervention groups were nine times more likely to have increased their physical activity by an hour or more per week, compared to patients in the control group. Those who were active for more than 150 minutes per week, and those who increased their level of fitness, also showed improvements in liver enzymes and other metabolic indices. The effect was independent of weight loss. Interestingly, there was no dose-response effect for exercise increases above 60 minutes per week. However, those who increased exercise by at least 60 minutes per week had beneficial changes in liver enzymes, insulin resistance and metabolic risk factors. While greater increases in exercise time appeared to be related to greater weight loss, there was no additional benefit to liver enzymes or glucose homeostasis. "The reason for this is unclear," the authors write, "but we hypothesize that the threshold for change in liver enzymes may be low so that even a slight increase in physical activity is sufficient to improve liver tests." Patients who remained sedentary over the course of the study had no improvement in metabolic parameters, and even trended toward deterioration in these areas, even if they lost weight. "The metabolic pathway by which physical activity improves insulin sensitivity may be different to that of weight loss and this is particularly relevant for patients with NAFLD," the authors write. "Physical activity improves insulin resistance through positive changes in fatty acid metabolism in muscle which cannot be achieved through energy restriction." "We have shown here that physical activity counseling can result in significant increases in physical activity and fitness and subsequent improvement in health, without the need for supervised exercise sessions," the authors conclude. Article: "The Independent Effects of Physical Activity in Patients with Non-Alcoholic Fatty Liver Disease." St. George, Alexis; Bauman, Adrian; Johnston, Amanda; Farrell, Geoff; Chey, Tien; George, Jacob. Hepatology; July 2009. Sean Wagner Wiley-Blackwell


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009